Compare EH & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | NNNN |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | China | Germany |
| Employees | N/A | 27 |
| Industry | Military/Government/Technical | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 417.8M |
| IPO Year | 2019 | N/A |
| Metric | EH | NNNN |
|---|---|---|
| Price | $4.91 | $9.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.47 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 39.3K |
| Earning Date | 05-26-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.23 | N/A |
| Revenue Next Year | $73.83 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.99 | $8.30 |
| 52 Week High | $20.33 | $54.90 |
| Indicator | EH | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 30.06 |
| Support Level | N/A | $8.30 |
| Resistance Level | $6.98 | $30.21 |
| Average True Range (ATR) | 0.33 | 1.33 |
| MACD | 0.06 | 0.43 |
| Stochastic Oscillator | 7.62 | 27.64 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).